Definitive Endoderm Differentiation via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating insulin-producing β-cells from human embryonic stem cells (hESCs) are inefficient, requiring large quantities of scarce islet cells and facing challenges in directed differentiation due to the pluripotency of hESCs, which leads to the production of various cell types at low efficiencies and the need for defining appropriate markers for successful cell therapy applications.
Innovation Solution
The development of methods to produce and isolate definitive endoderm cells, which can differentiate into cells of the gut tube or organs derived from it, using growth factors from the TGFβ superfamily such as Nodal, Activin, and BMP4, and markers like SOX17 and CXCR4 for enrichment and purification, allowing for the efficient production of pancreatic islet/β-cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hESCs are used for cell therapy applications, then a source of starting material is provided, but the cells differentiate into various cell types at low efficiencies due to pluripotency
Solution Approach 1:
The patent segments the differentiation process into distinct stages by introducing intermediate cell types (definitive endoderm, pancreatic endoderm) between hESCs and final β-cells. This segmentation allows for controlled progression through defined markers at each stage, improving overall differentiation efficiency while maintaining the pluripotent starting material advantage.
Solution Approach 2:
The patent employs preliminary action by pre-differentiating hESCs into definitive endoderm cells expressing specific markers (SOX17, CXCR4, GATA4) before further differentiation to pancreatic endoderm and β-cells. This staged approach with defined intermediate markers enables better control and efficiency at each differentiation step.
2Quantity of substance
If large quantities of islet cells are required for transplant, then sufficient material for therapy is obtained, but the scarcity of donor pancreases limits availability
Solution Approach 1:
The patent employs self-service by using hESCs as an autologous or allogeneic source that can be expanded and differentiated in culture to produce sufficient quantities of islet cells without requiring donor pancreases. The defined differentiation pathway with intermediate markers enables reliable production of therapeutic quantities from stem cell starting material.
3Measurement precision
If intermediate cell types are isolated and characterized, then appropriate lineage precursors are identified, but the complexity of defining markers increases
Solution Approach 1:
The patent segments the differentiation pathway into distinct stages, each characterized by specific marker expression patterns. Definitive endoderm is defined by SOX17+/CXCR4+/GATA4+, pancreatic endoderm by SOX17+/PDX1+, and β-cells by INS+/PDX1+. This segmentation provides clear, stage-specific markers that simplify identification and isolation at each step.
Solution Approach 2:
The patent uses parameter changes in marker expression levels and combinations to define intermediate cell types. Each stage transitions are marked by specific changes in marker profiles (e.g., loss of SOX17, gain of PDX1), providing precise biochemical parameters for identifying and isolating lineage precursors without excessive complexity.
Data Source
AI summary
Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.